Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial – AstraZeneca September 22, 2023
Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 Trial – Bristol-Myers Squibb July 11, 2023
AstraZeneca: Tagrisso-chemo combo improved progression-free survival in late-stage lung cancer trial – Endpoints News – Endpoints News May 17, 2023
Tagrisso plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial – AstraZeneca May 17, 2023